Tempest Net Income vs Depreciation Analysis

TPST Stock

USD 0.87 0.01 1.12%

Tempest Therapeutics financial indicator trend analysis is much more than just breaking down Tempest Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tempest Therapeutics is a good investment. Please check the relationship between Tempest Therapeutics Net Income and its Depreciation accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.

Net Income vs Depreciation

Net Income vs Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tempest Therapeutics Net Income account and Depreciation. At this time, the significance of the direction appears to have pay attention.

The correlation between Tempest Therapeutics' Net Income and Depreciation is -0.89. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Depreciation in the same time period over historical financial statements of Tempest Therapeutics, assuming nothing else is changed. The correlation between historical values of Tempest Therapeutics' Net Income and Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Tempest Therapeutics are associated (or correlated) with its Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation has no effect on the direction of Net Income i.e., Tempest Therapeutics' Net Income and Depreciation go up and down completely randomly.

Correlation Coefficient

-0.89

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Tempest Therapeutics financial statement analysis. It represents the amount of money remaining after all of Tempest Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Depreciation

Depreciation indicates how much of Tempest Therapeutics value has been used up. For tax purposes Tempest Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Tempest Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most indicators from Tempest Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tempest Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tempest Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Tempest Stock please use our How to Invest in Tempest Therapeutics guide.Selling General Administrative is likely to gain to about 15.4 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 1.2 M in 2024.

Tempest Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Net Debt	Retained Earnings	Cash	Common Stock Total Equity	Non Current Liabilities Total	Total Liab	Total Current Assets	Other Current Liab	Total Stockholder Equity	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Property Plant And Equipment Gross	Common Stock	Current Deferred Revenue	Short Long Term Debt Total	Net Receivables	Short Term Debt
Total Assets		0.74	-0.67	-0.73	0.63	0.74	-0.34	-0.17	1.0	0.67	0.78	0.39	0.8	0.36	0.6	0.93	-0.03	0.63	0.29	0.79	0.37	0.56	-0.04	-0.04	0.13	0.01
Total Current Liabilities	0.74		-0.57	-0.58	0.71	0.55	-0.18	0.05	0.72	0.91	0.45	0.38	0.36	0.35	0.38	0.55	0.18	0.17	0.77	0.59	0.4	0.15	-0.09	0.39	0.59	0.31
Net Debt	-0.67	-0.57		0.5	-0.92	-0.22	0.2	0.06	-0.69	-0.6	-0.49	-0.07	-0.39	0.05	-0.48	-0.63	0.19	-0.06	-0.39	-0.41	-0.04	-0.09	-0.11	0.12	-0.13	0.07
Retained Earnings	-0.73	-0.58	0.5		-0.53	-0.82	0.17	0.04	-0.7	-0.42	-0.49	-0.44	-0.52	-0.43	-0.9	-0.62	-0.19	-0.35	-0.11	-0.83	-0.44	-0.67	0.19	-0.12	0.11	-0.22
Cash	0.63	0.71	-0.92	-0.53		0.23	-0.11	0.06	0.62	0.6	0.37	0.36	0.2	0.23	0.49	0.49	0.18	-0.15	0.52	0.41	0.36	-0.07	-0.11	0.28	0.22	0.29
Common Stock Total Equity	0.74	0.55	-0.22	-0.82	0.23		-0.06	0.07	0.71	0.42	0.41	0.4	0.61	0.46	0.6	0.6	0.11	0.59	0.06	0.72	0.38	0.77	-0.12	0.06	-0.03	0.1
Non Current Liabilities Total	-0.34	-0.18	0.2	0.17	-0.11	-0.06		0.97	-0.36	-0.25	-0.81	0.09	-0.35	0.08	-0.35	-0.45	0.11	-0.37	-0.03	-0.62	0.04	-0.28	-0.04	0.19	-0.1	0.14
Total Liab	-0.17	0.05	0.06	0.04	0.06	0.07	0.97		-0.19	-0.03	-0.71	0.18	-0.27	0.16	-0.26	-0.33	0.15	-0.34	0.16	-0.49	0.14	-0.25	-0.06	0.29	0.04	0.22
Total Current Assets	1.0	0.72	-0.69	-0.7	0.62	0.71	-0.36	-0.19		0.69	0.8	0.3	0.81	0.27	0.58	0.95	-0.1	0.64	0.29	0.77	0.29	0.56	-0.01	-0.12	0.15	-0.05
Other Current Liab	0.67	0.91	-0.6	-0.42	0.6	0.42	-0.25	-0.03	0.69		0.51	0.09	0.41	0.07	0.24	0.6	-0.22	0.28	0.82	0.53	0.03	0.14	0.27	0.1	0.71	-0.08
Total Stockholder Equity	0.78	0.45	-0.49	-0.49	0.37	0.41	-0.81	-0.71	0.8	0.51		0.13	0.73	0.13	0.53	0.89	-0.19	0.7	0.12	0.83	0.12	0.55	0.09	-0.26	0.1	-0.21
Property Plant And Equipment Net	0.39	0.38	-0.07	-0.44	0.36	0.4	0.09	0.18	0.3	0.09	0.13		0.13	0.97	0.41	0.21	0.69	0.04	0.03	0.4	0.91	0.11	-0.3	0.73	-0.16	0.57
Accounts Payable	0.8	0.36	-0.39	-0.52	0.2	0.61	-0.35	-0.27	0.81	0.41	0.73	0.13		0.13	0.53	0.86	-0.34	0.84	-0.05	0.64	0.06	0.66	0.19	-0.44	-0.1	-0.38
Non Current Assets Total	0.36	0.35	0.05	-0.43	0.23	0.46	0.08	0.16	0.27	0.07	0.13	0.97	0.13		0.35	0.19	0.68	0.12	0.0	0.42	0.89	0.19	-0.29	0.72	-0.16	0.56
Non Currrent Assets Other	0.6	0.38	-0.48	-0.9	0.49	0.6	-0.35	-0.26	0.58	0.24	0.53	0.41	0.53	0.35		0.55	0.17	0.28	-0.05	0.79	0.39	0.57	-0.14	0.05	-0.25	0.13
Cash And Short Term Investments	0.93	0.55	-0.63	-0.62	0.49	0.6	-0.45	-0.33	0.95	0.6	0.89	0.21	0.86	0.19	0.55		-0.26	0.78	0.16	0.78	0.16	0.64	0.13	-0.3	0.07	-0.24
Common Stock Shares Outstanding	-0.03	0.18	0.19	-0.19	0.18	0.11	0.11	0.15	-0.1	-0.22	-0.19	0.69	-0.34	0.68	0.17	-0.26		-0.42	-0.04	0.07	0.87	-0.19	-0.82	0.84	-0.16	0.95
Short Term Investments	0.63	0.17	-0.06	-0.35	-0.15	0.59	-0.37	-0.34	0.64	0.28	0.7	0.04	0.84	0.12	0.28	0.78	-0.42		-0.17	0.6	-0.06	0.81	0.28	-0.49	-0.06	-0.48
Other Current Assets	0.29	0.77	-0.39	-0.11	0.52	0.06	-0.03	0.16	0.29	0.82	0.12	0.03	-0.05	0.0	-0.05	0.16	-0.04	-0.17		0.16	0.02	-0.32	0.15	0.37	0.91	0.15
Other Stockholder Equity	0.79	0.59	-0.41	-0.83	0.41	0.72	-0.62	-0.49	0.77	0.53	0.83	0.4	0.64	0.42	0.79	0.78	0.07	0.6	0.16		0.37	0.72	-0.03	0.05	0.06	0.05
Property Plant And Equipment Gross	0.37	0.4	-0.04	-0.44	0.36	0.38	0.04	0.14	0.29	0.03	0.12	0.91	0.06	0.89	0.39	0.16	0.87	-0.06	0.02	0.37		0.05	-0.64	0.77	-0.15	0.79
Common Stock	0.56	0.15	-0.09	-0.67	-0.07	0.77	-0.28	-0.25	0.56	0.14	0.55	0.11	0.66	0.19	0.57	0.64	-0.19	0.81	-0.32	0.72	0.05		0.04	-0.38	-0.3	-0.22
Current Deferred Revenue	-0.04	-0.09	-0.11	0.19	-0.11	-0.12	-0.04	-0.06	-0.01	0.27	0.09	-0.3	0.19	-0.29	-0.14	0.13	-0.82	0.28	0.15	-0.03	-0.64	0.04		-0.44	0.23	-0.85
Short Long Term Debt Total	-0.04	0.39	0.12	-0.12	0.28	0.06	0.19	0.29	-0.12	0.1	-0.26	0.73	-0.44	0.72	0.05	-0.3	0.84	-0.49	0.37	0.05	0.77	-0.38	-0.44		0.24	0.82
Net Receivables	0.13	0.59	-0.13	0.11	0.22	-0.03	-0.1	0.04	0.15	0.71	0.1	-0.16	-0.1	-0.16	-0.25	0.07	-0.16	-0.06	0.91	0.06	-0.15	-0.3	0.23	0.24		-0.01
Short Term Debt	0.01	0.31	0.07	-0.22	0.29	0.1	0.14	0.22	-0.05	-0.08	-0.21	0.57	-0.38	0.56	0.13	-0.24	0.95	-0.48	0.15	0.05	0.79	-0.22	-0.85	0.82	-0.01

Click cells to compare fundamentals

Tempest Therapeutics Account Relationship Matchups

Tempest Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	75.0M	22.9M	73.2M	46.1M	51.6M	70.9M
Total Current Liabilities	12.5M	3.2M	20.0M	7.3M	9.4M	9.6M
Net Debt	(59.0M)	(16.4M)	(33.3M)	(9.1M)	(18.6M)	(19.5M)
Retained Earnings	(208.7M)	(71.8M)	(100.1M)	(135.8M)	(165.3M)	(173.5M)
Cash	63.5M	18.8M	51.8M	31.2M	39.2M	35.9M
Liabilities And Stockholders Equity	75.0M	22.9M	73.2M	46.1M	51.6M	70.9M
Non Current Liabilities Total	2.6M	88.4M	17.1M	20.7M	15.4M	13.0M
Total Liab	15.1M	91.7M	37.1M	28.0M	24.8M	22.6M
Total Current Assets	71.1M	19.8M	69.0M	33.0M	40.4M	65.6M
Other Current Liab	9.1M	1.4M	16.2M	3.3M	2.4M	2.3M
Total Stockholder Equity	58.5M	(68.8M)	36.1M	18.1M	26.8M	37.9M
Accounts Payable	1.5M	1.1M	991K	1.1M	845K	1.4M
Non Current Assets Total	3.8M	3.0M	4.3M	13.1M	11.2M	5.7M
Non Currrent Assets Other	507.0K	51K	111K	429K	448K	405.2K
Cash And Short Term Investments	63.5M	18.8M	51.8M	31.2M	39.2M	48.4M
Common Stock Shares Outstanding	913.8K	31.2K	3.8M	11.5M	15.4M	16.2M
Other Current Assets	6.3M	745K	17.1M	1.4M	1.1M	1.1M
Other Stockholder Equity	215.0M	(170.9M)	136.2M	153.9M	192.0M	130.6M
Accumulated Other Comprehensive Income	(3.7M)	148K	165K	452K	(73.2M)	0.0
Short Long Term Debt Total	4.5M	2.4M	18.5M	22.1M	20.7M	12.6M
Net Receivables	1.3M	260K	15M	450K	517.5K	491.6K
Short Term Debt	2.0M	712K	2.9M	2.8M	6.2M	6.5M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Tempest Stock Analysis

When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC